Board of Directors

Collage of the Board of Directors in action. Photos are framed by white boarders

The IASLC’s multidisciplinary board brings a wealth of clinical and scientific thoracic oncology expertise, a close familiarity with institutional leadership and tremendous passion for ongoing improvements to care of patients with lung cancer. 

Board Officers 2023-2025

Image
Paul Van Schil

Paul Van Schil

President

Belgium

Dr. Paul Van Schil joined the IASLC Board of Directors in 2017 and has served as Chair of its Staging and Prognostic Factors Committee since 2017. He is now the current president-elect for the IASLC. 

Dr. Van Schil is a professor of thoracic and vascular surgery at the Faculty of Medicine, member of the Antwerp Surgical Training and Research Center (ASTARC) and consultant at the Department of Thoracic and Vascular Surgery of the Antwerp University Hospital.
His research focuses on thoracic and vascular surgery with an emphasis on lung cancer staging and therapy, lung metastases and mesothelioma. Dr. Van Schil has authored or co-authored nearly 250 articles and 44 book chapters. Dr. Van Schil graduated from medical school in 1982 at the Antwerp University in Belgium. After completing his training in general surgery, he became a fellow in the Department of Cardiothoracic Surgery at the Antonius Hospital, Nieuwegein, the Netherlands.

Image
Karen Kelly

Karen Kelly

Chief Executive Officer

United States

Dr. Kelly is the CEO of the International Association for the Study of Lung Cancer (IASLC), the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies. She is an internationally recognized lung cancer expert dedicated to providing enhanced cancer care through cutting-edge clinical trials. Her research spans the spectrum of this disease from prevention to treatment. Dr. Kelly is widely published, and she frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly is a long-standing active member of IASLC, ASCO, and SWOG. She served as the SWOG Lung Committee Chair from 2016 until 2022.

Dr. Kelly earned her medical degree from the University of Kansas School of Medicine. She completed her internal medicine residency and oncology fellowship at the University of Colorado Health Sciences Center in Denver, Colorado. Dr. Kelly was appointed faculty at the University of Colorado where she spent many years building her academic career in thoracic oncology prior to accepting a faculty appointment at the University of California, Davis where she held the Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Clinical Cancer Research and was the Associate Director for Clinical Research for their NCI designated comprehensive cancer center.

Image
Caicun Zhou

Caicun Zhou

President-Elect

China

Professor Caicun Zhou joined the IASLC Board of Directors in 2019, serving on the association’s Tobacco Control and Cessation Committee and Education Committee from 2010-2014.

With more than 20 years of experience in clinical oncology, Professor Zhou has focused his research on early detection, molecular targeted therapy, anti-angiogenesis therapy and immunotherapy in lung cancer. Since 1998, he has served as Chief Physician and Director of the Department of Medical Oncology at Tongji University in Shanghai Pulmonary Hospital. Prior to his work at Shanghai Pulmonary Hospital, he served as Associate Director at Affiliated Hospital of Bengbu Medical College.

Professor Zhou has published over 200 articles in international peer-reviewed journals, including the Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, and Annals of Oncology, and he has written three books on lung cancer. In 2002, he worked as a visiting scientist at the MD Anderson Cancer Center. He studied medicine at NanTong Medical College, earned his Ph.D. at China Medical University, and served as a fellow at Tokyo National Chest Hospital.

Image
Heather Wakelee

Heather Wakelee

Past-President

United States

Joining the Board of Directors in 2015, Dr. Heather Wakelee is a longtime IASLC member and the current President. She has served as Chair of the Communications Committee and has worked for more than a decade on various program committees for the World Conference on Lung Cancer.

Dr. Wakelee is a Professor of Medicine in the Division of Oncology at Stanford University and is the faculty director of the Stanford Cancer Clinical Trials Office. She has authored or co-authored over 200 articles on lung cancer and other thoracic malignancies, including thymic malignancies, and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics.

Her research focuses on specific lung cancer subtypes defined by mutations. She is also involved in trials of adjuvant therapy, immunotherapy and anti-angiogenesis agents in addition to collaborations with colleagues focused on biomarkers and population science research.

A graduate of Princeton University and Johns Hopkins University School of Medicine, Dr. Wakelee completed her post-graduate training at Stanford University.

Image
Ming Sound Tsao

Ming-Sound Tsao

Secretary

Canada

Dr. Tsao is a Consultant Pathologist, Senior Scientist at the Princess Margaret Cancer Centre. He is Professor of Laboratory Medicine and Pathobiology, and Professor of Medical Biophysics at the University of Toronto. His research focuses on understanding the genomic and molecular abnormalities in lung cancers to improve the accuracy of diagnosis and treatment. Dr. Tsao has made seminal contributions to the molecular characterization of lung cancer. His laboratory was one of the first to define molecular markers for patient selection towards treatment with targeted anti-cancer drugs, and defined gene signatures for outcome prediction of non-small-cell lung cancer patients. More recently, His laboratory has pioneered the establishment and characterization of patient-derived tumor models for lung cancer.  Dr. Tsao is Chair of the Correlative Science and Tumor Biology Committee of the Canadian Cancer Clinical Trials Group (CCTG), member and past Chair of the International Association for the Study of Lung Cancer (IASLC) Pathology Committee, the IASLC Staging & Prognostic Factor Committee, and a Standing Member of the Editorial Board for the WHO Books on Classification of Tumours 5th edition. He was an Associate Editor for the Journal of Thoracic Oncology and Editorial Board member of the Journal of Clinical Oncology. Dr. Tsao received the 2011 Canadian Cancer Society O. Harold Warwick Award, the 2016 IASLC Mary Matthew Pathology Award, and CCTG 2017 Dr. Joseph Pater Founder's Award for Excellence in Clinical Trials Research. In 2020, Dr. Tsao was elected a Fellow of the Royal Society of Canada. 

Image
Joachim Aerts

Joachim Aerts

Treasurer

Netherlands

Dr. Joachim Aerts is a board-certified pulmonologist with a special interest in thoracic oncology. He began his training as a pulmonologist in 1997 and became a board-certified pulmonologist in 2002. He subsequently worked in two teaching hospitals, during which he was appointed at the Erasmus University Rotterdam to organize and supervise the comprehensive cancer network in the southwest of The Netherlands and the basic, translational, and clinical research in oncology. He was appointed as professor of thoracic oncology in 2014 at Erasmus University Rotterdam. In 2018 he became head of the Department of respiratory medicine at the Erasmus University Medical Centre and, in 2021, division chair of the Department of respiratory medicine, cardiology, and thoracic surgery. 

During his professional career, Dr. Aerts has been heavily involved in many research projects and has initiated different basic, translational, and clinical studies, leading to over 200 peer-reviewed publications. He has supervised over 20 PhD students. Dr. Aerts is active in major scientific societies, both national and international, the IASLC, ASCO, ESMO, ERS, and ATS, and is frequently invited as a speaker and member of organizing committees. He is a member of the board of directors of the IASLC.

IASLC Board: 2023-2025

Image
Joe Chang

Joe Chang

Board Member

United States

Dr. Chang is a thoracic radiation oncologist with more than 30 years of experience with clinical care and research focusing on lung cancer. He holds a tenured Texas 4000 Distinguished Professorship and is Director of Stereotactic Ablative Radiotherapy at MD Anderson Cancer Center. He is a Fellow of the American Society of Radiation Oncology and has been recognized with the Best Doctors of America award. He is a voting committee member of NCCN thoracic guidelines and co-chair of the international particle therapy PTCOG scientific program committee. As one of the pioneers in the field of stereotactic ablative radiotherapy (SABR, or SBRT: stereotactic body radiation therapy), proton therapy, and immunotherapy for lung cancer, he published more than 300 peer-reviewed articles in prestigious journals, including LANCET, Nature, JAMA, Journal of Clinical Oncology, Journal of Thoracic Oncology, RED J, Green J, and various others. His prospective studies including randomized studies comparing surgery vs. SABR in operable stage I lung cancer, stereotactic proton vs. photon radiotherapy in challenging early-stage lung cancer, immunotherapy plus SABR (I-SABR) vs. SABR alone in early-stage lung cancer were the first reported studies in the world. He led the first concurrent proton therapy and chemotherapy in stage III lung cancer, and his team implemented the first intensity-modulated proton therapy (IMPT) in lung cancer. His research has helped to establish the role of SABR, proton therapy, and I-SABR in lung cancer. Additionally, on behalf of national and international societies, including the IASLC ART committee, he has led several important consensus statements that have significantly impacted the radiation oncology community about SABR, proton therapy in lung cancer, IMPT in moving thoracic cancers, management of small cell lung cancer, oligometastasis, and re-irradiation of thoracic cancer. 

Image
Carlos Gil Moreira Ferreira

Carlos Gil Moreira Ferreira

Board Member

Brazil

Dr. Carlos Gil Ferreira completed his training in Medical Oncology at the National Cancer Institute (INCA) in Rio de Janeiro in 1997, and his PhD in Experimental Oncology at the VUMC in Amsterdam in 2001 (under the supervision of Dr. Giuseppe Giaccone). 

His Lab at INCA pioneered some of the first local independent phase I, II and III trials, and biomarker validation studies in Brazil. Dr. Ferreira has published over 150 peer reviewed articles and book chapters.  One particular focus of his work has been the improvement of access to molecular testing in Brazil. Due to these efforts to broaden access to precision medicine, Dr. Ferreira received the Partners in Progress Award from ASCO in 2020.   

Dr. Ferreira’s group has developed multidisciplinary care for lung cancer, as well as improved the awareness of lung cancer.  He was awarded the Latin America Cancer Care Team Winner in 2017 and 2019 by the IASLC. 

Dr. Ferreira is an active member of the IASLC since 2003 and has served on the IASLC Fellowship Committee since 2013 (co-chair 2015-2017) and as a member of the IASLC Bylaws Committee.  He served as a member of the AACR International Affairs Committee between 2015-2018. 

From March 2018, Dr. Ferreira was appointed as President of the Oncoclinicas Institute and Chief Medical Officer of Oncoclinicas Group in Brazil. The main goal of his current work is continuous medical education in oncology and mentorship of young Brazilian oncologists. 

Image
Jhanelle Gray

Jhanelle Gray

Board Member

United States

Jhanelle E. Gray, M.D. is the Department Chair, Program Leader and a Senior Member for Thoracic Oncology at the Moffitt Cancer Center (MCC), Co-Leader of the Cancer Center Support Grant Molecular Medicine Program, and Professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. 

A renowned Thoracic medical oncologist and clinical investigator, Dr. Gray is actively involved and leads numerous clinical research trials that investigate novel immunotherapeutic and targeted therapy drug combinations for lung cancer which have greatly influenced standard of care treatment. Her research has generated over 80 publications in scholarly, peer-reviewed journals, including original manuscripts and reviews. A leader in NCI cooperative group trials and Chair of the IASLC Membership Committee, Dr. Gray received her Bachelor of Science from the University of Florida, Medical Degree from Cornell University Medical College, and completed her internship and residency in Internal Medicine at The New York Presbyterian Hospital - Cornell. Following, she completed her Hematology/Medical Oncology Fellowship at Moffitt Cancer Center. 

Dr. Gray is actively involved as a member of the MCC Scientific Leadership Council and Clinical Research Action Committee. Globally she is the American Society for Clinical Oncology (ASCO) 2022 Meeting Education Program Chair-elect while also serving as a member of the ASCO Lung Scientific Program Committee, IASLC Women in Thoracic Oncology Working Group and Southwest Oncology Group (SWOG) Lung Working Group.

Image
Young Tae Kim

Young Tae Kim

Board Member

South Korea

Dr. Kim graduated from Seoul National University College of Medicine and trained at Seoul National University Hospital Cardiovascular Surgical Residency Program and took the Advanced General Thoracic Surgical Fellowship Program at the Mayo Clinic, USA.  After military service, he joined the Department of Thoracic Surgery at Seoul National University Hospital as a faculty member.  

Dr. Kim is an active member of the IASLC, the American Association for Thoracic Surgery (AATS), the Society of Thoracic Surgeons (STS), and other international and domestic academic societies.  

Clinically, his main interest is lung cancer surgery.  Dr. Kim is one of the leading members of minimally invasive surgery and served as a board of directors for the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS).  

Academically, he has been conducting lung cancer genomic research. His group discovered KIF5B-RET fusion mutation in the lung adenocarcinoma for the first time in the world. After that, using whole-genome sequencing, his group found the genomic mechanism of fusion gene formation and published it in Cell.  Dr. Kim’s team has conducted various research solving the unmet needs of lung cancer genomics and leads the development of lung cancer panel tests in his institution. They established a lung alveolar organoid model to test SARS-CoV-2 infection, published in Cell Stem Cell.  

As the Chairman of KALC (Korean Association for Lung Cancer), Dr. Kim believes that international collaboration is critical to achieving the goal of conquering lung cancer, and he is encouraging the active participation of KALC members in the IASLC. 

Image
Natasha Leighl

Natasha Leighl

Board Member

Canada

Dr. Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, is a Professor of Medicine at the University of Toronto, and is an Adjunct Professor at the Institute of Health Policy, Management, and Evaluation at the Dalla Lana School of Public Health. She holds the Princess Margaret Cancer Foundation OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development. She has published over 350 peer-reviewed papers, held multiple peer-reviewed grants, and mentored many trainees who have gone on to leadership roles in oncology around the world. In 2019, she was awarded the American Society of Clinical Oncology Excellence in Teaching Award. Her passion for improving patient care has driven her research in lung cancer drug development lung cancer diagnostics, including liquid biopsy, guideline development, and outcomes research.

She has led several international and cooperative group studies in lung cancer, served on the Lung Disease Site Group Executive of the Canadian Cancer Clinical Trials Group (CCTG), was Co-Chair of the CCTG Committee on Economic Analysis, Congress Co-President of the 2018 World Conference on Lung Cancer, and serves on the ASCO Thoracic Guidelines Advisory Group, ESMO Guidelines Group (Lead, non-metastatic lung cancer), is Faculty Coordinator (Metastatic Lung Cancer) for the ESMO Education Committee, Chair of the International Society of Liquid Biopsy Education Committee and co-Chair of the 2024 European Lung Cancer Congress. She is Deputy Editor of Critical Reviews in Hematology/Oncology, Section co-editor of Therapeutic Advances in Medical Oncology, and serves on multiple editorial boards, including the Journal of Thoracic Oncology, and was a previous Web Editor. She is a strong supporter of patient advocacy and serves on the Scientific Advisory Board of the Lung Cancer Foundation of America, she is the Past President of Lung Cancer Canada (2009-2016) and an Honorary Chair of the Exon20 Group. 

 

Image
Morten Quist

Morten Quist

Board Member

Denmark

Dr. Quist is an associate professor at the Copenhagen University and a Physiotherapist clinician-researcher with 20 years expertise in exercise for patients with cancer at the University Hospital of Copenhagen (Rigshospitalet). He is the co-founder of the “body and Cancer” and founder of the EXHALE program.  He received a PhD from The University of Copenhagen in 2015 on the topic of Exercise and Advanced Stage Lung Cancer.  Dr. Quist’s research area is exercise and lung cancer in all stages (early and advance) and in different treatment modalities (diagnostic, surgery, chemotherapy, radiotherapy, and immunotherapy). His focus is to prepare patients for treatment, optimizing functional capacity, and maintaining or improving quality of life.

Dr. Quist served on the board of directors of the Danish Lung Cancer Group in 2017 and was responsible for developing guidelines for rehabilitation in lung cancer in Denmark. He has been a member of the IASLC Nurses and Allied Health Professionals Committee since 2017.   

In addition to research, Dr. Quist co-founded and co-created two exercise communities in Denmark (Proof of Life and PACT) for cancer survivors and patients with cancer. Proof of life is an exercise community for young cancer survivors and PACT (physical activity after cancer treatment) is an exercise community for cancer patients. He received the Danish Cancer Society honor award in 2015 for his voluntary work to keep patients with cancer active, and in 2017 received the IASLC Nursing and Allied Health Lectureship Award.

Image
Antoni Rosell

Antoni Rosell

Board Member

Spain

Dr. Antoni Rosell (Barcelona, 1963) Pulmonologist (1992), PhD in Medicine (2000), Diploma in Biostatistics (2004), European Certification in Respiratory Medicine (HERMES) (2009), and Professor of Medicine at the Universitat Autònoma de Barcelona (2021), he has held the position of Chief of Respiratory Endoscopy Unit of the Hospital Universitari de Bellvitge (Barcelona) between 2005 and 2018. Since then, he is the Clinical Director of the Thoracic Institute of the Hospital Universitari of the Germans Trias I Pujol Hospital (Barcelona), managing the Pulmonology Service and the Thoracic Surgery Service. He has made short stages in international hospitals and research centers between 1998 and 2013, learning autofluorescence, endobronchial ultrasound (EBUS), rigid bronchoscopy, and lung cancer screening programs. He has been the introducer in Spain of the EBUS, the autofluorescence bronchoscopy, and the non-electromagnetic navigation system (Archimedes©). During 2012-2018, he developed an international fellowship on interventional bronchoscopy. He is a referral in this field, specifically rigid bronchoscopy and stenting. He leads the Translational Pulmonology Research Group of the Germans Trias Research Institute (IGTP).

Dr. Rosell is a reviewer of research projects of various public health agencies and international journals. He published 22 articles in Q1, h-Index of 16, and is the co-author of 3 patents. Together with the group of chemists, an antibiofilm silver-eluting stent was developed and tested in an animal model. His research is focused on radiomics and radiogenomics applied in lung cancer screening, and he is participating in the International Lung Screen Trial (ISLT). He chaired the 3rd European Congress of the EABIP (European Association for Bronchology and Interventional Pulmonology) in 2015 and was the vice president of the World Conference on Lung Cancer (WCLC) in Barcelona (2019). 

Image
Dr. Lecia Sequist

Lecia Sequist

Board Member

United States

Dr. Sequist is originally from Michigan and studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty at the Massachusetts General Hospital Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Professor of Medicine at Harvard Medical School and the Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and novel technologies to detect cancer earlier. In her free time, she likes to spend time with her husband, two sons, and her dog, read and travel. 

Image
Benjamin Solomon

Benjamin Solomon

Board Member

Australia

Professor Benjamin Solomon is a medical oncologist and head of the lung medical oncology service at the Peter MacCallum Cancer Centre in Melbourne, Australia. Following his training in medical oncology, he was a recipient of an IASLC fellowship in 2004 and proceeded to do a postdoctoral fellowship at the University of Colorado under the supervision of Professors Paul Bunn and Fred Hirsch. He returned to Peter MacCallum Cancer Centre in 2006, where he heads the Lung Medical Oncology Service and is a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division. His clinical trial work focuses on the identification of novel therapies for lung cancer, including novel targeted therapy and immunotherapy approaches. He has been involved in practice-changing clinical trials with novel inhibitors of ALK, ROS1, NTRK, BRAF, cMET, RET, and KRAS, including pivotal trials leading to registration of drugs including crizotinib, ceritinib, lorlatinib, repotrectinib, and selpercatinib.

He has more than 200 peer-reviewed publications and has been recognized as a Clarivate Highly Cited Researcher (2019, 2020, 2021, 2022). He is a founding board member of the Thoracic Oncology Group of Australasia (TOGA) and is a Board Member of the Cancer Council of Victoria. He has served on several committees for the IASLC, including the fellowship committee, and was chair from 2016-2018. 

Image
Paula Ugalde

Paula Ugalde

Board Member

United States

Dr. Paula Ugalde graduated in 1995 and by 2000 completed training in thoracic surgery in Brazil. She did her postdoctoral research and obtained a master’s degree in 2004 when she became an assistant professor at the Federal University of Bahia Medical School. For the next 3-years, Dr. Ugalde completed a fellowship in Thoracic Surgery at Laval University in Quebec, Canada, and in 2007-2008, a Thoracic Surgery Fellowship at the University of Pittsburgh Medical Center. In 2013, she was recruited back to Quebec and began as an associate professor at Laval University. She was soon named director of the Thoracic Oncology research program. 

Dr. Ugalde established herself as a thoracic surgeon dedicated to research with an extensive record of publications, including a body of work on thoracic surgery using innovative approaches for lung cancer. Dr. Ugalde oversaw the creation of the lung cancer database at Laval University, and the university became the largest contributor in the world of cases to the IASLC database. She was awarded the IASLC Clifton F. Mountain Lectureship Award in 2019 and appointed Chair of the Database Committee of SPFC of the IASLC. In 2019, she was accepted as a member of the AATS. She has performed peer-review for the society’s journals as well as for other journals, including the EJCTS, and given lectures at AATS symposia and worldwide. Additionally, she introduced minimally invasive thoracic surgery in Brazil and Latin America and continues to pursue this mission as co-chair of International Affairs for the Women in Thoracic Surgery Society. 

Image
Ignacio Wistuba

Ignacio Wistuba

Board Member

United States

Dr. Ignacio Wistuba is Professor and Chair of the Department of Translational Molecular Pathology with joint appointment in the Department of Thoracic/Head and Neck Medical Oncology (THNMO) and co-director of the Khalifa Institute of Personalized Cancer Institute at the University of Texas MD Anderson Cancer Center, Houston, USA. He obtained his medical doctorate from Universidad Austral, Valdivia, Chile (1985), and completed surgical pathology training at Catholic University, Santiago, Chile (1989). Then, he trained for nearly five years as a post-doctoral research fellow in lung cancer molecular pathology at the Hamon Cancer Center at The University of Texas Southwestern Medical Center in Dallas, USA, under the mentorship of Drs. Adi Gazdar and John Minna (1994-1999). After spending five years in Chile as a professor of pathology at Catholic University Medical School, Dr. Wistuba joined MD Anderson Cancer Center in 2003 in the departments of Pathology and THNMO to lead a lung cancer molecular pathology program. His major research interest is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer and the development of predictive biomarkers for targeted and immune-oncology therapies.

He has co-authored over 750 papers in peer-reviewed journals and several book chapters. He is the principal investigator (PI) and co-PI on several molecular pathology and biomarker projects supported by multi-investigators and multi-institutional grants and research agreements in thoracic malignancies. Dr. Wistuba has been highly involved in IASLC activities for the last 17 years by serving as a member of various committees, including the Pathology Committee that he chaired from 2017-2020. Since moving to the United States in 2023, Dr. Wistuba has participated as a member of scientific organizing committees, speaker, and attendee to all WCLC and LALCA meetings and several regional IASLC meetings. He received IASLC's Mary J. Matthews Pathology/Translational Research Award in 2018. 

Image
Wenzhao Zhong

Wen-Zhao Zhong

Board Member

China

Wen-Zhao Zhong received his Ph.D. in Oncology, specializing in thoracic surgery, from Sun Yat-Sen University, Guangzhou, China. At present, he is serving as the chief physician of thoracic neoplasms surgery at Guangdong Lung Cancer Institute. Wen-Zhao is broadly interested in the area of clinical trials and translational research involving early-stage and locally advanced non-small cell lung cancer, which include systemic treatment modality of stage III non-small cell lung cancer (NSCLC), personalized perioperative treatment, diagnosis and management of pulmonary nodules as well as early screening of lung cancer. His recent projects involve personalized treatment modalities for localized mutant non-small cell lung cancer and ctDNA-guided personalized treatment.

Recent relevant research has been published in high-impact journals such as the Journal of Clinical Oncology, NPJ Precision Oncology, Journal of Thoracic Oncology, etc. In 2022 WCLC, he achieved the TSUGUO NARUKE Lectureship award for surgery in recognition of his outstanding contribution to the field of thoracic oncology and particularly to thoracic surgery. 

Collage of the Board of Directors in action. Photos are framed by white boarders

COI for Board of Directors

On an annual basis, all members of the IASLC Board of Directors must affirm their understanding of and agreement to comply with IASLC policies, standards, and instructions including, but not limited to, the items detailed below.

Communications Committee

Committees

One of the unique benefits of an IASLC membership is the opportunity to serve on an IASLC committee in a volunteer capacity. 

IASLC at WCLC 2023

Our Staff

The staff of the IASLC is united in a shared passion to conquer lung cancer by serving its members worldwide.